Literature DB >> 19075046

New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Jossy van den Boogaard1, Gibson S Kibiki, Elton R Kisanga, Martin J Boeree, Rob E Aarnoutse.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19075046      PMCID： PMC2650526          DOI： 10.1128/AAC.00749-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  167 in total

1.  Two three-month treatment regimens for pulmonary tuberculosis.

Authors:  B Kreis; S Pretet; J Birenbaum; P Guibout; J J Hazeman; E Orin; S Perdrizet; J Weil
Journal:  Bull Int Union Tuberc       Date:  1976

2.  The rapid development of fluoroquinolone resistance in M. tuberculosis.

Authors:  Amy Sarah Ginsburg; Samuel C Woolwine; Nancy Hooper; William H Benjamin; William R Bishai; Susan E Dorman; Timothy R Sterling
Journal:  N Engl J Med       Date:  2003-11-13       Impact factor: 91.245

3.  Rifabutin in the treatment of newly diagnosed pulmonary tuberculosis.

Authors:  D A Mitchison
Journal:  Tuber Lung Dis       Date:  1995-06

4.  Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong.

Authors:  C M Tam; S L Chan; C W Lam; J M Dickinson; D A Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  1997-10       Impact factor: 2.373

5.  Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results.

Authors:  G Valerio; P Bracciale; V Manisco; M Quitadamo; G Legari; S Bellanova
Journal:  J Chemother       Date:  2003-02       Impact factor: 1.714

6.  In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis.

Authors:  J M Dickinson; D A Mitchison
Journal:  Tubercle       Date:  1987-06

Review 7.  The clinical use of fluoroquinolones for the treatment of mycobacterial diseases.

Authors:  G J Alangaden; S A Lerner
Journal:  Clin Infect Dis       Date:  1997-11       Impact factor: 9.079

8.  In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

Authors:  B Ji; N Lounis; C Maslo; C Truffot-Pernot; P Bonnafous; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

9.  Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.

Authors:  Anne J Lenaerts; Donald Hoff; Sahar Aly; Stefan Ehlers; Koen Andries; Luis Cantarero; Ian M Orme; Randall J Basaraba
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

10.  Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharat; R K Shandil; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191
View more
  54 in total

1.  Local control of pulmonary resistance and lung compliance in the canine lung.

Authors:  R L Coon; C C Rattenborg; J P Kampine
Journal:  J Appl Physiol       Date:  1975-10       Impact factor: 3.531

2.  Study of interactions between Mycobacterium tuberculosis proteins: SigK and anti-SigK.

Authors:  Vasavi Malkhed; Bargavi Gudlur; Bhargavi Kondagari; Ramasree Dulapalli; Uma Vuruputuri
Journal:  J Mol Model       Date:  2010-07-31       Impact factor: 1.810

3.  Drug-resistant tuberculosis: pediatric guidelines.

Authors:  Navaneetha Pandian Poorana Ganga Devi; Soumya Swaminathan
Journal:  Curr Infect Dis Rep       Date:  2013-10       Impact factor: 3.725

4.  Evolution of Rifampin Resistance in Escherichia coli and Mycobacterium smegmatis Due to Substandard Drugs.

Authors:  Zohar B Weinstein; Muhammad H Zaman
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

5.  Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

Authors:  Ciaran Skerry; Michael L Pinn; Natalie Bruiners; Richard Pine; Maria L Gennaro; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2014-05-22       Impact factor: 5.790

6.  The domain architecture of PtkA, the first tyrosine kinase from Mycobacterium tuberculosis, differs from the conventional kinase architecture.

Authors:  Anna Niesteruk; Hendrik R A Jonker; Christian Richter; Verena Linhard; Sridhar Sreeramulu; Harald Schwalbe
Journal:  J Biol Chem       Date:  2018-06-08       Impact factor: 5.157

7.  Reconsidering some approved antimicrobial agents for tuberculosis.

Authors:  Lowell S Young
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

Review 8.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

9.  Development of cyclobutene- and cyclobutane-functionalized fatty acids with inhibitory activity against Mycobacterium tuberculosis.

Authors:  Wantanee Sittiwong; Denise K Zinniel; Robert J Fenton; Darrell D Marshall; Courtney B Story; Bohkyung Kim; Ji-Young Lee; Robert Powers; Raúl G Barletta; Patrick H Dussault
Journal:  ChemMedChem       Date:  2014-06-05       Impact factor: 3.466

10.  Effects of pyridoxine on the intestinal absorption and pharmacokinetics of isoniazid in rats.

Authors:  Yan Zhou; Yang Jiao; Yu-Hui Wei; Guo-Rong Zhang; Jian-Ping Zhang; Jiang-Xia Ren; Fan Zhang; Guo-Qiang Zhang; Hao-Gang Duan; Xin-An Wu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-10-23       Impact factor: 2.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.